AVEO Pharmaceuticals Phase 3 top-line data TIVO-3 – tivozanib

September 3, 2018 @ 6:48 pm – February 2, 2019 @ 7:48 pm

AVEO Pharmaceuticals has Phase 3 top-line data for it’s TIVO-3 in the 4th Quarter of 2018. TIVO-3 is designed to support regulatory approval of tivozanib in the U.S. as a first- and third-line treatment for aRCC.

AVEO Pharmaceuticals has ALOT of insider buying, which would lead me to believe the insiders are bullish on the results and this stock could keep going up into the 4th quarter catalyst.

I think it could get into the $3 range before it’s Phase 3 top-line data for TIVO-3 catalyst event.

With currently (according to Finviz) $.23 /share and 118M shares, which is about $27M, the company should have enough cash on hand not to do an offering before the catalyst event. I would like to get an entry below $2.50.